Live telerobotic procedure broadcast from Mayo Clinic to TCT Main Arena
WALTHAM, MA – September 24, 2018 — Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced the first live transmission of a remote interventional procedure using the company’s CorPath® platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego, CA on September 22, 2018. The remote interventional procedure was broadcast live from Mayo Clinic to the TCT Main Arena. Utilizing CorPath GRX with developmental remote technology, combined with a telecommunications system to enable communication with the bedside staff, the operator at Mayo Clinic had the ability to remotely manipulate interventional devices within a porcine model's arteries while located in a different building.
The global shortage of skilled specialists who can treat emergent conditions, such as a heart attack or acute ischemic stroke, is significant and continues to be a growing problem. Remote treatment has the potential to enable physicians to conduct procedures from virtually any location, opening opportunities for more patients globally to receive the benefits of lifesaving procedures where minimizing time to treatment is critical.
Earlier this year, Mayo Clinic received a $3.3 million grant from The Leona M. and Harry B. Helmsley Charitable Trust to support a multi-phase, multi-year development program for remote robotic technology. Mayo Clinic is working with Corindus to explore telerobotics as a new treatment paradigm that gives rural and underserved populations across the globe access to time-critical vascular therapies.
"We believe it fitting that the first-ever live transmission of a remote interventional procedure took place at the 30 th anniversary of the TCT meeting. Interventional cardiovascular medicine has made great strides in the last 30 years, and this milestone case represents an important forward step as we advance the access and treatment of coronary artery and other vascular diseases," stated Martin Leon, M.D., Founder of the Cardiovascular Research Foundation.
"We have made significant progress in early evaluations of remote procedures, showing the feasibility and benefit that telerobotics can provide to patients globally. We were pleased to be a part of the first live transmission of a telerobotic procedure which highlighted the advancements that we have made in collaboration with our clinical partners," said Mark Toland, President and CEO of Corindus. "We will continue advancing remote technology to transform the care model for patients with conditions where time to treatment and access to skilled specialists are paramount."
Transcatheter Cardiovascular Therapeutics (TCT) is the world’s largest and most important educational meeting specializing in interventional cardiovascular medicine. For 30 years, TCT has been the center of cutting-edge educational content, showcasing the latest advances in current therapies and clinical research. The symposium is designed for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, andextend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. For additional information, visit www.corindus.com, and follow @CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward- looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.
Examples of such statements include statements regarding or such as:
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: our ability to expand our technology platform and achieve the advances necessary for telestenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries; risks associated with market acceptance; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; and potential safety and regulatory issues that could slow or suspend our sales. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at www.corindus.com.